Trial Profile
Does dipeptidyl peptidase IV (DPP-IV) inhibition (vildagliptin) potentiate the effects of intraduodenal fat on glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), and thereby reduce energy intake and postprandial triglycerides, and increase energy expenditure and fat oxidation in healthy lean males?
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Jul 2016
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary) ; Soya oil emulsion
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Novartis Pharmaceuticals
- 29 Oct 2015 New trial record